Vernakalant (oral) is being investigated as a chronic-use oral drug for the maintenance of normal heart rhythm following termination of AF. Cardiome announced positive results from a Phase 2a pilot study for vernakalant (oral) in September 2006. A Phase 2b study for vernakalant (oral) is ongoing.
In April 2007 Cardiome acquired exclusive worldwide rights for GED-aPC for all indications. Cardiome intends to initially develop GED-aPC in cardiogenic shock, a life-threatening form of acute circulatory failure due to cardiac dysfunction, which is a leading cause of death for patients hospitalized following a heart attack.
Cardiome is traded on the Toronto Stock Exchange (COM) and the NASDAQ National Market (CRME).
Forward-Looking Statement Disclaimer
Certain statements in this press release contain forward-looking
statements within the meaning of the Private Securities Litigation Reform
Act of 1995 or forward-looking information under applicable Canadian
securities legislation that may not be based on historical fact, including
without limitation statements containing the words "believe", "may",
"plan", "will", "estimate", "continue", "anticipate", "intend", "expect"
and similar expressions. Such forward-looking statements or information
involve known and unknown risks, uncertainties and other factors that may
cause our actual results, events or developments, or industry results, to
be materially different from any future results, events or developments
expressed or implied by such forward-looking statements or information.
Such factors include, among others, our stage of development, lack of
product revenues, additional capital requirements, risk associated with the
completion of clinical trials and obtaining regulatory approval to market
our products, the ability to protect our intellectual property, dependence
on collaborative partners and the prospect
|SOURCE Cardiome Pharma Corp.|
Copyright©2008 PR Newswire.
All rights reserved